BioSpace News Archive

Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced new data supporting novel capabilities of its CRISPR/Cas9 genome editing platform, which the Company plans to leverage for the development of future therapeutic candidates.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into a collaboration agreement with Ab Magnitude Ventures Group, LLC and Ab Magnitude Fund, LP (collectively, “Ab Magnitude”) for the development of next-generation targeted oncology therapeutics.

F-star Therapeutics, Ltd. today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Akouos, Inc. today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27 at 9:30 a.m. EDT.

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the acceptance for presentation of three abstracts at industry conferences.

Novome Biotechnologies, Inc. today announced the appointment of Bill McLeod as Chief Financial Officer.

the Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced positive topline results from the EMERALD study.

Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world’s most prevalent eye diseases, today announced publication in the journal Cornea of positive results from OLYMPIA, a multicenter, investigator-masked, randomized controlled trial.

TCR 2 Therapeutics Inc. today unveiled new programs and provided highlights from its emerging TRuC pipeline programs during its first virtual R&D Day.

Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin’s senior management team to discuss the Company’s third quarter 2021 financial results on Wednesday, November 3, 2021, at 7:30 a.m. ET.